Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945457 | 1.00 | TSHR (0.35) | TSHRALDH1A1LPAR1LPAR2LPAR3 | |
| SCHEMBL28294021 | 0.83 | — | — | |
| SCHEMBL7942943 | 0.81 | LPAR1 (0.34) | TSHRALDH1A1LPAR1LPAR2LPAR3 | |
| SCHEMBL7942945 | 0.81 | LPAR1 (0.34) | TSHRALDH1A1LPAR1LPAR2LPAR3 | |
| SCHEMBL16994989 | 0.80 | THRB (0.41) | TSHRLPAR1LPAR2LPAR3CA1 | |
| SCHEMBL23501869 | 0.79 | LPAR3 (0.41) | ALDH1A1LPAR1LPAR2LPAR3 | |
| SCHEMBL14939724 | 0.79 | THRB (0.38) | TSHRLPAR1LPAR2LPAR3CA1 | |
| SCHEMBL905315 | 0.79 | THRB (0.38) | TSHRLPAR1LPAR2LPAR3CA1 | |
| SCHEMBL489185 | 0.79 | THRB (0.38) | TSHRLPAR1LPAR2LPAR3CA1 | |
| SCHEMBL14939723 | 0.79 | THRB (0.38) | TSHRLPAR1LPAR2LPAR3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307434-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-06-04 | — | — | US | disclosed |
| US-9744183-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2017-08-29 | — | — | US | disclosed |
| US-20160347784-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES PTE. LTD. (SG) | 2016-12-01 | — | — | US | disclosed |
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | ONTORII, INC (US) | 2012-12-13 | — | — | US | disclosed |
| EP-2451461-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | Ontorii, Inc (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005761-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS USE THEREOF | ONTORII, INC (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | PNP, RNGTT, TYMP | TSHR 3172/4885ALDH1A1 1085/4885LPAR1 1571/4885 |
| US-20160347784-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | PNP, RNGTT, TYMP | TSHR 3172/4885ALDH1A1 1085/4885LPAR1 1571/4885 |
| US-10307434-B2 | Nucleic acid prodrugs and methods of use thereof | PNP, RNGTT, NSUN2 | TSHR 3338/4885ALDH1A1 899/4885LPAR1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.